类风湿关节炎患者妊娠期用药趋势及不良妊娠结局影响因素
基于韩国国家健康保险数据库2010至2020年的5728次妊娠事件,比较分娩组4576次与不良妊娠结局组1152次的用药特征。妊娠期所有改善病情抗风湿药处方率快速下降;受孕前3个月内使用甲氨蝶呤(aOR 2.14,95%CI 1.57至2.92)和来氟米特(aOR 2.68,95%CI 1.39至5.15)与不良妊娠结局相关。
要点
- 受孕前3个月内使用甲氨蝶呤与不良妊娠结局相关(aOR 2.14,95%CI 1.57至2.92)。
- 受孕前3个月内使用来氟米特与不良妊娠结局相关(aOR 2.68,95%CI 1.39至5.15)。
- 妊娠期所有改善病情抗风湿药处方率快速下降,羟氯喹为两组最常用传统合成改善病情抗风湿药。
核心结论
- 甲氨蝶呤和来氟米特与不良妊娠结局可能性增加相关,作者强调计划妊娠时适当调整用药的重要性。
研究设计与样本
- 从韩国国家健康保险数据库2010至2020年识别20至50岁女性类风湿关节炎患者,妊娠事件按结局分为分娩组与不良妊娠结局组(流产和死胎),比较两组特征与用药模式,并进行多因素logistic回归分析。
主要发现
- 共纳入5728次妊娠事件,其中分娩组4576次、不良妊娠结局组1152次。
- 全部妊娠事件母亲平均年龄33.7岁,分娩组33.3岁、不良妊娠结局组33.7岁。
- 羟氯喹是两组受孕前及妊娠期最常用的传统合成改善病情抗风湿药。
- 妊娠期所有改善病情抗风湿药的处方率快速下降。
- 多因素分析中,受孕前3个月内使用甲氨蝶呤(aOR 2.14,95%CI 1.57至2.92)与使用来氟米特(aOR 2.68,95%CI 1.39至5.15)与不良妊娠结局相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: We aimed to investigate medication utilisation trends during pregnancy and identify factors associated with adverse pregnancy outcomes (APOs) in patients with rheumatoid arthritis (RA). METHODS: Female patients with RA aged 20-50 years were identified from the Korean national health insurance database between 2010 and 2020. Pregnancy episodes were divided into two groups according to pregnancy outcome: the delivery group and the APO group (abortion and stillbirth). The characteristics and medication utilisation patterns were compared between the two groups, and multivariable logistic regression analysis was conducted to identify the factors associated with APOs. RESULTS: A total of 5728 pregnancy episodes were included, comprising 4576 delivery episodes and 1152 APO episodes. The mean maternal age for all pregnancy episodes was 33.7 years; 33.3 years in the delivery group and 33.7 years in the APO group. Hydroxychloroquine was the most commonly used conventional synthetic disease-modifying antirheumatic drug (DMARD) during the preconception period and pregnancy in both groups. The prescription rate of all DMARDs decreased rapidly during pregnancy. In the multivariable analysis, use of methotrexate (adjusted OR (aOR): 2.14, 95% CI 1.57 to 2.92) and leflunomide (aOR: 2.68, 95% CI 1.39 to 5.15) within 3 months before conception was associated with APOs. CONCLUSION: Methotrexate and leflunomide are associated with an increased possibility of APOs, emphasising the importance of appropriate medication adjustment when planning for pregnancy.
引用
- Song YJ, Cho SK, Jung YS, et al. Medication utilisation trends during pregnancy and factors influencing adverse pregnancy outcomes in patients with rheumatoid arthritis. RMD Open. 2024. PMID: 38519107. doi:10.1136/rmdopen-2023-003739
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。